Blackstone Closes Record $6.3B Life Sciences Fund, Largest Private Equity Vehicle in Sector History
Blackstone has closed the largest life sciences private equity fund ever raised at $6.3 billion, nearly 40% larger than its $4.6 billion predecessor from 2020.
Blackstone has closed the largest life sciences private equity fund ever raised at $6.3 billion, nearly 40% larger than its $4.6 billion predecessor from 2020.
The Fund
- Size: $6.3 billion (record for life sciences PE)
- Growth: ~40% larger than previous fund (2020)
- Platform: Blackstone Life Sciences (BXLS), launched 2018
- Assets under management: $15 billion (as of late 2025)
- Parent: Blackstone, the world's largest PE firm ($1T+ AUM)
Track Record
BXLS partnerships have produced:
- 34 approved innovative medicines and devices
- 86% approval rate for late-stage assets (outperforming industry average)
- Major financed medicines: Leqvio (cholesterol), Amvuttra (rare disease), Imbruvica (blood cancer)
Recent Major Deals
| Deal | Amount | Partner |
|---|---|---|
| Teva gut disease drug R&D | $400M | Teva Pharmaceutical |
| Merck cancer ADC royalties | $700M | Merck & Co. |
| Anthos Therapeutics acquisition | $3.1B | Novartis (buyer) |
| J&J AML drug R&D | Undisclosed | Johnson & Johnson |
Why It Matters
This record fund signals massive institutional confidence in life sciences investing. Blackstone's model — providing capital in exchange for future drug royalties — is becoming a dominant financing mechanism for biopharma innovation.
The fund's scale allows Blackstone to participate in the largest and most complex biopharma transactions, effectively competing with traditional pharma M&A as a source of capital for drug development.
← Previous: Wireless Light Chip Could Boost Internet Speeds While Cutting Energy UseNext: Eli Lilly Acquires Centessa for $6.3B to Bolster Neuroscience Pipeline with Sleep Disorder Drugs →
0